Arrowhead Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARWR and other ETFs, options, and stocks.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. 

CEO
Christopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees
711
Employees711
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1989
Founded1989
Employees
711
Employees711

ARWR Key Statistics

Market cap
9.10B
Market cap9.10B
Price-Earnings ratio
-1,024.26
Price-Earnings ratio-1,024.26
Dividend yield
Dividend yield
Average volume
4.06M
Average volume4.06M
High today
$68.82
High today$68.82
Low today
$65.93
Low today$65.93
Open price
$67.98
Open price$67.98
Volume
1.47M
Volume1.47M
52 Week high
$71.50
52 Week high$71.50
52 Week low
$9.57
52 Week low$9.57

Stock Snapshot

With a market cap of 9.1B, Arrowhead Pharmaceuticals(ARWR) trades at $66.97. The stock has a price-to-earnings ratio of -1024.26.

As of 2025-12-10, Arrowhead Pharmaceuticals(ARWR) stock has fluctuated between $65.93 and $68.82. The current price stands at $66.97, placing the stock +1.6% above today's low and -2.7% off the high.

Arrowhead Pharmaceuticals(ARWR) shares are trading with a volume of 1.47M, against a daily average of 4.06M.

In the last year, Arrowhead Pharmaceuticals(ARWR) shares hit a 52-week high of $71.50 and a 52-week low of $9.57.

In the last year, Arrowhead Pharmaceuticals(ARWR) shares hit a 52-week high of $71.50 and a 52-week low of $9.57.

ARWR News

TipRanks 17h
Director Cashes in on Arrowhead Pharmaceuticals Stock!

New insider activity at Arrowhead Pharmaceuticals ( (ARWR) ) has taken place on December 9, 2025. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for...

TipRanks 1d
Analyst Recommends Buy Rating for Arrowhead Pharmaceuticals Due to Promising Obesity Treatment Potential

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $85.00. TipRanks Cyber Monday Sale...

Simply Wall St 2d
Arrowhead Pharmaceuticals Is Up 22.0% After FDA Grants Breakthrough Status to Plozasiran

Arrowhead Pharmaceuticals recently reported that the FDA granted Breakthrough Therapy designation to its investigational RNAi drug plozasiran as an add-on to di...

Arrowhead Pharmaceuticals Is Up 22.0% After FDA Grants Breakthrough Status to Plozasiran

Analyst ratings

64%

of 14 ratings
Buy
64.3%
Hold
35.7%
Sell
0%

More ARWR News

TipRanks 2d
Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor’s Positive Obesity Treatment Data

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Arrowhead Pharmaceuticals, with a price target of $48.00. TipRanks Cyber...

Simply Wall St 5d
Arrowhead Pharmaceuticals Valuation After FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals (ARWR) just got a meaningful regulatory boost, with the FDA granting Breakthrough Therapy designation to its triglyceride lowering dru...

Arrowhead Pharmaceuticals Valuation After FDA Breakthrough Therapy Designation for Plozasiran

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.